US 12358968
Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
granted A61KA61K2239/46A61K35/17
Quick answer
US patent 12358968 (Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer) held by Providence Health & Services—Oregon expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Providence Health & Services—Oregon
- Grant date
- Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K2239/46, A61K35/17, A61K38/00, A61K40/11